Trial Profile
A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2013
Price :
$35
*
At a glance
- Drugs Silibinin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Rottapharm Madaus
- 28 Feb 2012 New trial record